Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 87 entries
Sorted by: Best Match Show Resources per page
Medical-legal partnerships: addressing competency needs through lawyers.

Journal of graduate medical education

Paul E, Fullerton DF, Cohen E, Lawton E, Ryan A, Sandel M.
PMID: 21975996
J Grad Med Educ. 2009 Dec;1(2):304-9. doi: 10.4300/JGME-D-09-00016.1.

BACKGROUND: Many low- and moderate-income individuals and families have at least one unmet legal need (for example, unsafe housing conditions, lack of access to food and/or income support, lack of access to health care), which, if left unaddressed, can...

Cite
Paul E, Fullerton DF, Cohen E, et al. Medical-legal partnerships: addressing competency needs through lawyers. J Grad Med Educ. 2009;1(2):304-9doi: 10.4300/JGME-D-09-00016.1.
Paul, E., Fullerton, D. F., Cohen, E., Lawton, E., Ryan, A., & Sandel, M. (2009). Medical-legal partnerships: addressing competency needs through lawyers. Journal of graduate medical education, 1(2), 304-9. https://doi.org/10.4300/JGME-D-09-00016.1
Paul, Edward, et al. "Medical-legal partnerships: addressing competency needs through lawyers." Journal of graduate medical education vol. 1,2 (2009): 304-9. doi: https://doi.org/10.4300/JGME-D-09-00016.1
Paul E, Fullerton DF, Cohen E, Lawton E, Ryan A, Sandel M. Medical-legal partnerships: addressing competency needs through lawyers. J Grad Med Educ. 2009 Dec;1(2):304-9. doi: 10.4300/JGME-D-09-00016.1. PMID: 21975996; PMCID: PMC2931240.
Copy Download .nbib Format: NLM
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Frontiers in immunology

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.
PMID: 28659916
Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for...

Cite
Erbe AK, Wang W, Reville PK, et al. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017;8:675doi: 10.3389/fimmu.2017.00675.
Erbe, A. K., Wang, W., Reville, P. K., Carmichael, L., Kim, K., Mendonca, E. A., Song, Y., Hank, J. A., London, W. B., Naranjo, A., Hong, F., Hogarty, M. D., Maris, J. M., Park, J. R., Ozkaynak, M. F., Miller, J. S., Gilman, A. L., Kahl, B., Yu, A. L., & Sondel, P. M. (2017). HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in immunology, 8675. https://doi.org/10.3389/fimmu.2017.00675
Erbe, Amy K, et al. "HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy." Frontiers in immunology vol. 8 (2017): 675. doi: https://doi.org/10.3389/fimmu.2017.00675
Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017. PMID: 28659916; PMCID: PMC5466980.
Copy Download .nbib Format: NLM
Axonal outgrowth in muscle grafts made acellular by chemical extraction.

Restorative neurology and neuroscience

Arai T, Kanje M, Lundborg G, Sondell M, Liu XL, Dahlin LB.
PMID: 11490088
Restor Neurol Neurosci. 2000;17(4):165-174.

Purpose: To compare nerve regeneration in autologous detergent extracted and freeze-thawed muscle grafts and to electrophoretically characterize the grafts. Methods: Autologous acellular muscie grafts were created either by freeze/thawing or by detergent extraction and then used to bridge a...

Cite
Arai T, Kanje M, Lundborg G, et al. Axonal outgrowth in muscle grafts made acellular by chemical extraction. Restor Neurol Neurosci. 2000;17(4):165-174
Arai, T., Kanje, M., Lundborg, G., Sondell, M., Liu, X. L., & Dahlin, L. B. (2000). Axonal outgrowth in muscle grafts made acellular by chemical extraction. Restorative neurology and neuroscience, 17(4), 165-174.
Arai, Takeru, et al. "Axonal outgrowth in muscle grafts made acellular by chemical extraction." Restorative neurology and neuroscience vol. 17,4 (2000): 165-174.
Arai T, Kanje M, Lundborg G, Sondell M, Liu XL, Dahlin LB. Axonal outgrowth in muscle grafts made acellular by chemical extraction. Restor Neurol Neurosci. 2000;17(4):165-174. PMID: 11490088.
Copy Download .nbib Format: NLM
Health impact assessments.

Rhode Island medical journal (2013)

Suther E, Sandel M.
PMID: 23819138
R I Med J (2013). 2013 Jul 01;96(7):27-30.

Health Impact Assessment (HIA) serves as a tool for policymakers and planners when considering a new policy, project, or plan that will influence the health of people outside of the doctor's office. HIA is a series of steps that...

Cite
Suther E, Sandel M. Health impact assessments. R I Med J (2013). 2013;96(7):27-30
Suther, E., & Sandel, M. (2013). Health impact assessments. Rhode Island medical journal (2013), 96(7), 27-30.
Suther, Emily, and Sandel, Megan. "Health impact assessments." Rhode Island medical journal (2013) vol. 96,7 (2013): 27-30.
Suther E, Sandel M. Health impact assessments. R I Med J (2013). 2013 Jul 01;96(7):27-30. PMID: 23819138.
Copy Download .nbib Format: NLM
Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction.

Immunology today

Mandell RB, Sondel PM.
PMID: 25291000
Immunol Today. 1985 Nov;6(11):321-3. doi: 10.1016/0167-5699(85)90126-4.

Synthetic and environmental antigens are presented to T cells in the context of MHC determinants but, for certain antigens, some determinants are more effective than others(1-3), perhaps because they make an optimal or more immunogenic physical association with the...

Cite
Mandell RB, Sondel PM. Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction. Immunol Today. 1985;6(11):321-3doi: 10.1016/0167-5699(85)90126-4.
Mandell, R. B., & Sondel, P. M. (1985). Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction. Immunology today, 6(11), 321-3. https://doi.org/10.1016/0167-5699(85)90126-4
Mandell, R B, and Sondel, P M. "Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction." Immunology today vol. 6,11 (1985): 321-3. doi: https://doi.org/10.1016/0167-5699(85)90126-4
Mandell RB, Sondel PM. Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction. Immunol Today. 1985 Nov;6(11):321-3. doi: 10.1016/0167-5699(85)90126-4. PMID: 25291000.
Copy Download .nbib Format: NLM
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.

Oncoimmunology

Ayuso JM, Truttschel R, Gong MM, Humayun M, Virumbrales-Munoz M, Vitek R, Felder M, Gillies SD, Sondel P, Wisinski KB, Patankar M, Beebe DJ, Skala MC.
PMID: 30723584
Oncoimmunology. 2018 Dec 12;8(3):1553477. doi: 10.1080/2162402X.2018.1553477. eCollection 2019.

Immunotherapies against solid tumors face additional challenges compared with hematological cancers. In solid tumors, immune cells and antibodies need to extravasate from vasculature, find the tumor, and migrate through a dense mass of cells. These multiple steps pose significant...

Cite
Ayuso JM, Truttschel R, Gong MM, et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology. 2018;8(3):1553477doi: 10.1080/2162402X.2018.1553477.
Ayuso, J. M., Truttschel, R., Gong, M. M., Humayun, M., Virumbrales-Munoz, M., Vitek, R., Felder, M., Gillies, S. D., Sondel, P., Wisinski, K. B., Patankar, M., Beebe, D. J., & Skala, M. C. (2019). Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology, 8(3), 1553477. https://doi.org/10.1080/2162402X.2018.1553477
Ayuso, Jose M, et al. "Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model." Oncoimmunology vol. 8,3 (2019): 1553477. doi: https://doi.org/10.1080/2162402X.2018.1553477
Ayuso JM, Truttschel R, Gong MM, Humayun M, Virumbrales-Munoz M, Vitek R, Felder M, Gillies SD, Sondel P, Wisinski KB, Patankar M, Beebe DJ, Skala MC. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology. 2018 Dec 12;8(3):1553477. doi: 10.1080/2162402X.2018.1553477. eCollection 2019. PMID: 30723584; PMCID: PMC6350694.
Copy Download .nbib Format: NLM
P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.

The American journal of gastroenterology

Sands B, Pondel M, Silver M, Petersen A, Wolf D, Panaccione R, Loftus E, Colombel JF, Sturm A, D'Haens G.
PMID: 35006159
Am J Gastroenterol. 2021 Dec 01;116:S8. doi: 10.14309/01.ajg.0000798724.11932.76.

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, demonstrated superior efficacy and safety vs placebo for up to 52 weeks in adults with moderately to severely active ulcerative colitis (UC) in a phase...

Cite
Sands B, Pondel M, Silver M, et al. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. Am J Gastroenterol. 2021;116:S8doi: 10.14309/01.ajg.0000798724.11932.76.
Sands, B., Pondel, M., Silver, M., Petersen, A., Wolf, D., Panaccione, R., Loftus, E., Colombel, J. F., Sturm, A., & D'Haens, G. (2021). P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. The American journal of gastroenterology, 116S8. https://doi.org/10.14309/01.ajg.0000798724.11932.76
Sands, Bruce, et al. "P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study." The American journal of gastroenterology vol. 116 (2021): S8. doi: https://doi.org/10.14309/01.ajg.0000798724.11932.76
Sands B, Pondel M, Silver M, Petersen A, Wolf D, Panaccione R, Loftus E, Colombel JF, Sturm A, D'Haens G. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. Am J Gastroenterol. 2021 Dec 01;116:S8. doi: 10.14309/01.ajg.0000798724.11932.76. PMID: 35006159.
Copy Download .nbib Format: NLM
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

PloS one

Magee K, Marsh IR, Turek MM, Grudzinski J, Aluicio-Sarduy E, Engle JW, Kurzman ID, Zuleger CL, Oseid EA, Jaskowiak C, Albertini MR, Esbona K, Bednarz B, Sondel PM, Weichert JP, Morris ZS, Hernandez R, Vail DM.
PMID: 34383787
PLoS One. 2021 Aug 12;16(8):e0255798. doi: 10.1371/journal.pone.0255798. eCollection 2021.

RATIONALE: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety and feasibility of this approach...

Cite
Magee K, Marsh IR, Turek MM, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021;16(8):e0255798doi: 10.1371/journal.pone.0255798.
Magee, K., Marsh, I. R., Turek, M. M., Grudzinski, J., Aluicio-Sarduy, E., Engle, J. W., Kurzman, I. D., Zuleger, C. L., Oseid, E. A., Jaskowiak, C., Albertini, M. R., Esbona, K., Bednarz, B., Sondel, P. M., Weichert, J. P., Morris, Z. S., Hernandez, R., & Vail, D. M. (2021). Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PloS one, 16(8), e0255798. https://doi.org/10.1371/journal.pone.0255798
Magee, Kara, et al. "Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting." PloS one vol. 16,8 (2021): e0255798. doi: https://doi.org/10.1371/journal.pone.0255798
Magee K, Marsh IR, Turek MM, Grudzinski J, Aluicio-Sarduy E, Engle JW, Kurzman ID, Zuleger CL, Oseid EA, Jaskowiak C, Albertini MR, Esbona K, Bednarz B, Sondel PM, Weichert JP, Morris ZS, Hernandez R, Vail DM. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021 Aug 12;16(8):e0255798. doi: 10.1371/journal.pone.0255798. eCollection 2021. PMID: 34383787; PMCID: PMC8360580.
Copy Download .nbib Format: NLM
Radiation Augments the Local Anti-Tumor Effect of .

Frontiers in immunology

Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, Birstler J, Le T, Carlson PM, Bates AM, Hank JA, Rakhmilevich AL, Erbe AK, Sondel PM, Patel RB, Morris ZS.
PMID: 34868010
Front Immunol. 2021 Nov 15;12:763888. doi: 10.3389/fimmu.2021.763888. eCollection 2021.

INTRODUCTION: Combining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective METHODS: Mice bearing flank tumors (A20 lymphoma, B78 melanoma or 4T1 breast cancer) were treated with combinations of local RT, CpG, and/or OX40, and...

Cite
Pieper AA, Zangl LM, Speigelman DV, et al. Radiation Augments the Local Anti-Tumor Effect of . Front Immunol. 2021;12:763888doi: 10.3389/fimmu.2021.763888.
Pieper, A. A., Zangl, L. M., Speigelman, D. V., Feils, A. S., Hoefges, A., Jagodinsky, J. C., Felder, M. A., Tsarovsky, N. W., Arthur, I. S., Brown, R. J., Birstler, J., Le, T., Carlson, P. M., Bates, A. M., Hank, J. A., Rakhmilevich, A. L., Erbe, A. K., Sondel, P. M., Patel, R. B., & Morris, Z. S. (2021). Radiation Augments the Local Anti-Tumor Effect of . Frontiers in immunology, 12763888. https://doi.org/10.3389/fimmu.2021.763888
Pieper, Alexander A, et al. "Radiation Augments the Local Anti-Tumor Effect of ." Frontiers in immunology vol. 12 (2021): 763888. doi: https://doi.org/10.3389/fimmu.2021.763888
Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, Birstler J, Le T, Carlson PM, Bates AM, Hank JA, Rakhmilevich AL, Erbe AK, Sondel PM, Patel RB, Morris ZS. Radiation Augments the Local Anti-Tumor Effect of . Front Immunol. 2021 Nov 15;12:763888. doi: 10.3389/fimmu.2021.763888. eCollection 2021. PMID: 34868010; PMCID: PMC8634717.
Copy Download .nbib Format: NLM
A modality-specific somatosensory evoked potential test protocol for clinical evaluation: A feasibility study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Fabig SC, Kersebaum D, Lassen J, Sendel M, Jendral S, Muntean A, Baron R, Hüllemann P.
PMID: 34740042
Clin Neurophysiol. 2021 Dec;132(12):3104-3115. doi: 10.1016/j.clinph.2021.08.017. Epub 2021 Sep 27.

OBJECTIVE: We aimed to establish an objective neurophysiological test protocol that can be used to assess the somatosensory nervous system.METHODS: In order to assess most fiber subtypes of the somatosensory nervous system, repetitive stimuli of seven different modalities (touch,...

Cite
Fabig SC, Kersebaum D, Lassen J, et al. A modality-specific somatosensory evoked potential test protocol for clinical evaluation: A feasibility study. Clin Neurophysiol. 2021;132(12):3104-3115doi: 10.1016/j.clinph.2021.08.017.
Fabig, S. C., Kersebaum, D., Lassen, J., Sendel, M., Jendral, S., Muntean, A., Baron, R., & Hüllemann, P. (2021). A modality-specific somatosensory evoked potential test protocol for clinical evaluation: A feasibility study. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 132(12), 3104-3115. https://doi.org/10.1016/j.clinph.2021.08.017
Fabig, Sophie-Charlotte, et al. "A modality-specific somatosensory evoked potential test protocol for clinical evaluation: A feasibility study." Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology vol. 132,12 (2021): 3104-3115. doi: https://doi.org/10.1016/j.clinph.2021.08.017
Fabig SC, Kersebaum D, Lassen J, Sendel M, Jendral S, Muntean A, Baron R, Hüllemann P. A modality-specific somatosensory evoked potential test protocol for clinical evaluation: A feasibility study. Clin Neurophysiol. 2021 Dec;132(12):3104-3115. doi: 10.1016/j.clinph.2021.08.017. Epub 2021 Sep 27. PMID: 34740042.
Copy Download .nbib Format: NLM
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

Clinical cancer research : an official journal of the American Association for Cancer Research

Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM.
PMID: 33504555
Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27.

PURPOSE: Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolidation therapy. These results served as the...

Cite
Yu AL, Gilman AL, Ozkaynak MF, et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179-2189doi: 10.1158/1078-0432.CCR-20-3909.
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., Naranjo, A., Diccianni, M. B., Gan, J., Hank, J. A., Batova, A., London, W. B., Tenney, S. C., Smith, M., Shulkin, B. L., Parisi, M., Matthay, K. K., Cohn, S. L., Maris, J. M., Bagatell, R., Park, J. R., & Sondel, P. M. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(8), 2179-2189. https://doi.org/10.1158/1078-0432.CCR-20-3909
Yu, Alice L, et al. "Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,8 (2021): 2179-2189. doi: https://doi.org/10.1158/1078-0432.CCR-20-3909
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27. PMID: 33504555; PMCID: PMC8046731.
Copy Download .nbib Format: NLM
Muscle fibrils: Solubilization and gel electrophoresis.

FEBS letters

Sender PM.
PMID: 11946008
FEBS Lett. 1971 Sep 15;17(1):106-110. doi: 10.1016/0014-5793(71)80575-6.

No abstract available.

Cite
Sender PM. Muscle fibrils: Solubilization and gel electrophoresis. FEBS Lett. 1971;17(1):106-110doi: 10.1016/0014-5793(71)80575-6.
Sender, P. M. (1971). Muscle fibrils: Solubilization and gel electrophoresis. FEBS letters, 17(1), 106-110. https://doi.org/10.1016/0014-5793(71)80575-6
Sender, P M.. "Muscle fibrils: Solubilization and gel electrophoresis." FEBS letters vol. 17,1 (1971): 106-110. doi: https://doi.org/10.1016/0014-5793(71)80575-6
Sender PM. Muscle fibrils: Solubilization and gel electrophoresis. FEBS Lett. 1971 Sep 15;17(1):106-110. doi: 10.1016/0014-5793(71)80575-6. PMID: 11946008.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 87 entries